Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia
Menno Vergeer and John JP Kastelein*
Correspondence *Department of Vascular Medicine, Academic Medical Center, Room F4-159.2, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Email j.j.kastelein@amc.uva.nl
This article has no abstract so we have provided the first paragraph of the full text.
A low level of HDL cholesterol is among the strongest predictors of cardiovascular disease. Several studies have confirmed the atheroprotective potential of the HDL particle. In cholesterol-fed rabbits, injected HDL plasma fractions were shown to induce regression of atherosclerotic lesions.1 Furthermore, disruptive mutations in the gene coding for apolipoprotein A-I—the major structural apolipoprotein of HDL—have been shown to lead to very low HDL-cholesterol levels, as well as to increased risk of premature coronary artery disease in humans.2 These data have aroused considerable interest in the development of new pharmacological strategies to increase HDL levels and thereby counteract atherosclerosis.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
